vTv Therapeutics (NASDAQ:VTVT – Get Free Report)‘s stock had its “buy” rating reiterated by BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $57.00 price target on the biotechnology company’s stock. BTIG Research’s price objective would indicate a potential upside of 98.89% from the stock’s current price.
A number of other research analysts have also weighed in on VTVT. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $67.00 target price on the stock. HC Wainwright cut their price target on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Wall Street Zen upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 3rd. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. Finally, Weiss Ratings cut vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, vTv Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.83.
Read Our Latest Research Report on VTVT
vTv Therapeutics Stock Up 1.5%
vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.08). As a group, analysts expect that vTv Therapeutics will post -2.35 earnings per share for the current fiscal year.
About vTv Therapeutics
vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.
vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.
Featured Stories
- Five stocks we like better than vTv Therapeutics
- Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built
- Albertsons Is Betting on a Turnaround—But Will It Pay Off?
- Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit
- PepsiCo’s Earnings Beat Masks a Bigger Problem With Its North American Business
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
